Detection of Minimal Residual Disease Post-prostatectomy

Recruiting now

Conditions studied: Prostate Cancer

In brief

The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.

Key facts

Study ID

NCT07334275

Run by

Radboud University Medical Center

People needed

50

Starts

2025-09-16

Expected to finish

2028-01-01

Last updated by the study team

2026-01-12

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male aged 18 years or older;
• High-risk prostate cancer, defined as:
• High-risk localized prostate cancer, with PSA level >20 ng/mL, Gleason score 8-10 (ISUP grade 4/5) at prostate biopsies, or iT3a (based on multi-parametric MRI of the prostate); or
• High-risk locally advanced prostate cancer, having any PSA level, any Gleason score/ISUP grade, iT3b-4 (based on multi-parametric MRI of the prostate) or iN1 (based on PSMA PET/CT imaging);
• Scheduled for robot-assisted radical prostatectomy;
• Willingness to consent to both patient information sheets regarding tissue and liquid biobanking.

You may not qualify if…

• Relevant contra-indications that may limit clinical follow-up or blood collection, as assessed by the including physician.

Where it is running

• Prosper Prostate Cancer Clinics — Nijmegen, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.